Last Updated on February 4, 2021 by The Health Master
Dr Reddy’s Laboratories Ltd announced the launch of vigabatrin tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril (vigabatrin) tablets, USP, approved by the US Food and Drug Administration (USFDA).
“We are pleased that this product has been designated as a competitive generic therapy (CGT) by the FDA,” says Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories.
The Sabril brand and generic had US sales of approximately US$ 141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health.
Dr Reddy’s vigabatrin tablets, USP are available in 500 mg tablets in a bottle count size of 100.
Also read:
Granules India gets USFDA nod for Potassium Chloride Oral Solution
Glenmark gets USFDA nod for Amphetamine Sulfate tablets
Unichem gets USFDA nod for Zonisamide Capsules
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
